Literature DB >> 17917098

Tamoxifen induced-thrombocytopenia: it does occur.

Narin Nasiroğlu1, Merve Pamukçuoğlu, Hüseyin Abali, Berna Oksüzoğlu, Ayşegül Uner, Nurullah Zengin.   

Abstract

Tamoxifen has been in the center of management of hormone-sensitive breast cancer. Furthermore, it represents the best example of chemo-prevention: It reduces the incidence of invasive breast cancer. However, it has some side effects, several of them are severe. Oncologists, hematologists, internal medicine specialists and gynecologists must know this agent in detail. Authors report a very rare side effect, thrombocytopenia, and discuss it briefly.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17917098     DOI: 10.1007/s12032-007-0013-0

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  6 in total

1.  Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

Authors: 
Journal:  Lancet       Date:  1998-05-16       Impact factor: 79.321

2.  Thrombocytopenia after combination therapy with aminoglutethimide and tamoxifen: which drug is to blame?

Authors:  J Ragaz; N Buskard; M Manji
Journal:  Cancer Treat Rep       Date:  1984 Jul-Aug

Review 3.  Tamoxifen-induced thrombocytopenia.

Authors:  J C Yao; N Thomakos; P McLaughlin; T A Buchholz; A P Kudelka
Journal:  Am J Clin Oncol       Date:  1999-10       Impact factor: 2.339

4.  Tamoxifen-induced tissue factor pathway inhibitor reduction: a clue for an acquired thrombophilic state?

Authors:  M Erman; H Abali; B Oran; I C Haznedaroglu; H Canpinar; S Kirazli; I Celik
Journal:  Ann Oncol       Date:  2004-11       Impact factor: 32.976

5.  Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.

Authors:  B Fisher; J P Costantino; D L Wickerham; C K Redmond; M Kavanah; W M Cronin; V Vogel; A Robidoux; N Dimitrov; J Atkins; M Daly; S Wieand; E Tan-Chiu; L Ford; N Wolmark
Journal:  J Natl Cancer Inst       Date:  1998-09-16       Impact factor: 13.506

6.  Tamoxifen-induced immune-mediated platelet destruction. A case report.

Authors:  A Candido; S Bussa; R Tartaglione; R Mancini; C Rumi; P Rossi; B Bizzi
Journal:  Tumori       Date:  1993-06-30
  6 in total
  1 in total

1.  Tamoxifen and arrhythmia.

Authors:  Ladislav Slovacek; Peter Priester; Jiri Petera; Jindrich Kopecky
Journal:  Med Oncol       Date:  2010-12       Impact factor: 3.064

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.